BridgeBio Pharma Inc (BBIO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ... [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Royalty Revenue: $4.3 million from ex-US net sales of Beyonttra in Europe and Japan. License and Services Revenue: $8.3 million. Operating Expenses: $259.3 million, up from $193.9 million in the prior year. SG&A Expenses Increase: $68.8 million. Cash Position: $645.9 million in cash, cash equivalents, and marketable securities. Warning! GuruFocus has detected 6 Warning Signs with BBIO. Is BBIO fairly valued? Test your thesis with our free DCF calculator. Release Date: October 29, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points BridgeBio Pharma Inc ( NASDAQ:BBIO ) reported strong commercial execution with Attruby, achieving $108.1 million in net product sales for the quarter. The company announced positive Phase 3 results for BBP-418 in limb-girdle muscular dystrophy type 2i and encaleret in autosomal dominant hypocalcemia type 1, exceeding expectations. BridgeBio Pharma Inc ( NASDAQ:BBIO
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio to Participate in December Investor ConferencesGlobeNewswire
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Wells Fargo & Company from $76.00 to $84.00. They now have an "overweight" rating on the stock.MarketBeat
- BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]Seeking Alpha
- AbCellera Appoints Dr. Stephen Quake to its Board of Directors [Yahoo! Finance]Yahoo! Finance
BBIO
Earnings
- 10/29/25 - Miss
BBIO
Sec Filings
- 11/24/25 - Form 4
- 11/20/25 - Form 144
- 11/19/25 - Form 4
- BBIO's page on the SEC website